Reportlinker Adds Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Mar 29, 2011, 06:31 ET from Reportlinker

NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

http://www.reportlinker.com/p0464104/Cancer-Supportive-Care-Products-Market-to-2016---Market-is-Expected-to-Decline-after-2014-Due-to-Generic-Erosion-and-Entry-of-Biosimilars.html

Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

Summary

GBI Research, the leading business intelligence provider, has released its latest research, "Cancer Supportive Care Products Market to 2016 – Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars", which provides insights into the cancer supportive care products market and forecasts until 2016. The report provides an in-depth analysis of the six major cancer supportive care products indications, which are oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases. The report also looks into the major unmet needs in the cancer supportive care products market and the major classes of drugs that treat the indications covered in the sector. The report also analyzes the key drivers and restraints that are expected to impact each of the indications in the global cancer supportive care products market. The report also delves into the cancer supportive care products market in the top seven countries in the world, which includes the US, the UK, Germany, France, Italy, Spain and Japan. In addition, the report also includes insights into the R&D (Research & Development) pipeline for the six cancer supportive care indications. In addition, the report also looks into the major M&A (Mergers & Acquisitions) and licensing deals that have taken place between 2008 and 2010 in the global cancer supportive care products market space.

Scope

The scope of this report includes -

- Data and analysis on the cancer supportive care products market.

- Annualized market data for the cancer supportive care products market from 2001 to 2009, with forecasts to 2016.

- Market data on the therapeutic landscape which covers oral mucositis and dry mouth, chemotherapy-induced nausea and vomiting, cancer pain, chemotherapy-induced anemia, chemotherapy-induced neutropenia and bone metastases, including market size, market share, annual cost of therapy, treatment usage patterns such as prevalence population and prescription population.

- Key drivers and restraints that have had a significant impact on the market and on each indication.

- The geographic landscape that covers the US, the top five countries of Europe (the UK, France, Germany, Spain and Italy) and Japan.

- The competitive landscape of the cancer supportive care products market which includes companies such as Amgen, Johnson & Johnson, Roche, Novartis and Pfizer

- Key M&A activities and Licensing Agreements that took place from 2008 to 2010 in the cancer supportive care products market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading countries and therapeutic segments poised for strong growth.

- Devise a more tailored country strategy through the understanding of key drivers and barriers of each region's pharmaceutical market.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.

Table of Contents

1 Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Cancer Supportive Care Products Market: Introduction 12

2.1 GBI Research Report Guidance 12

3 Cancer Supportive Care Products Market: Market Overview 13

3.1 Revenue 13

3.2 Average Annual Cost of Therapy 14

3.3 Therapeutic Segmentation 15

3.4 Geographic Segmentation 16

3.5 Generic Share in the Cancer Supportive Care Products Market 20

3.6 Drivers and Restraints of Cancer Supportive Care Products Market 21

3.6.1 Drivers 21

3.6.2 Restraints 22

3.7 Unmet Needs 23

3.7.1 Efficacy 23

3.7.2 Safety 23

3.7.3 Price 23

3.8 Major Drug Classes 24

3.8.1 Anti-infectives (Oral Mucositis) 24

3.8.2 Anti-emetics (CINV) 24

3.8.3 Bisphosphonates (Bone Metastases) 25

3.8.4 Erythropoietin Stimulating Agents (CIA) 25

3.8.5 Granulocyte Colony Stimulating Factors (CINP) 26

3.8.6 Opioid Analgesics (Cancer Pain and Bone Metastases) 26

3.8.7 NSAIDs (Cancer Pain and Bone Metastases) 26

3.8.8 Monoclonal Antibodies (Bone Metastases) 27

4 Cancer Supportive Care Products Market: Therapeutic Landscape 28

4.1 Oral Mucositis and Dry Mouth Market 28

4.1.1 Introduction 28

4.1.2 Revenue 29

4.1.3 Annual Cost of Therapy 30

4.1.4 Treatment Usage Patterns 31

4.1.5 Drivers for the Oral Mucositis and Dry Mouth Market 33

4.1.6 Restraints for the Oral Mucositis and Dry Mouth Market 34

4.1.7 Geographical Segmentation 34

4.2 Chemotherapy Induced Nausea and Vomiting Market 38

4.2.1 Introduction 38

4.2.2 Revenue 40

4.2.3 Annual Cost of Therapy 41

4.2.4 Treatment Usage Patterns 42

4.2.5 Drivers for the Chemotherapy Induced Nausea and Vomiting Market 44

4.2.6 Restraints for the Chemotherapy Induced Nausea and Vomiting Market 45

4.2.7 Geographical Landscape 46

4.3 Cancer Pain Market 49

4.3.1 Introduction 49

4.3.2 Revenue 49

4.3.3 Annual Cost of Therapy 50

4.3.4 Treatment Usage Patterns 51

4.3.5 Drivers for the Cancer Pain Market 56

4.3.6 Restraints for the Cancer Pain Market 56

4.3.7 Geographical Landscape 57

4.4 Chemotherapy Induced Anemia Market 60

4.4.1 Introduction 60

4.4.2 Revenue 60

4.4.3 Annual Cost of Therapy 62

4.4.4 Treatment Usage Patterns 63

4.4.5 Drivers for the Chemotherapy Induced Anemia Market 66

4.4.6 Restraints for the Chemotherapy Induced Anemia Market 66

4.4.7 Geographical Landscape 67

4.5 Chemotherapy Induced Neutropenia Market 70

4.5.1 Introduction 70

4.5.2 Revenue 71

4.5.3 Annual Cost of Therapy 72

4.5.4 Treatment Usage Patterns 73

4.5.5 Drivers for the Chemotherapy Induced Neutropenia Market 76

4.5.6 Restraints for the Chemotherapy Induced Neutropenia Market 76

4.5.7 Geographical Landscape 77

4.6 Bone Metastases Market 79

4.6.1 Introduction 79

4.6.2 Revenue 80

4.6.3 Annual Cost of Therapy 81

4.6.4 Treatment Usage Patterns 82

4.6.5 Drivers for the Bone Metastases Market 85

4.6.6 Restraints for the Bone Metastases Market 85

4.6.7 Geographical Landscape 86

5 Cancer Supportive Care Products Market: Geographical Landscape 89

5.1 The US 89

5.1.1 Revenue 89

5.1.2 Average Annual Cost of Therapy 90

5.1.3 Therapeutic Segmentation 91

5.2 Top Five Countries of Europe 92

5.2.1 Revenue 92

5.2.2 Average Annual Cost of Therapy 93

5.2.3 Therapeutic Segmentation 94

5.2.4 Geographic Segmentation 95

5.3 Japan 96

5.3.1 Revenue 96

5.3.2 Average Annual Cost of Therapy 97

5.3.3 Therapeutic Segmentation 98

6 Cancer Supportive Care Products Market: Pipeline Analysis 99

6.1 Introduction 99

6.1.1 Research and Development Pipeline – Oral Mucositis and Dry Mouth 101

6.1.2 Research and Development Pipeline – Chemotherapy Induced Nausea and Vomiting 102

6.1.3 Research and Development Pipeline – Cancer Pain 103

6.1.4 Research and Development Pipeline – Chemotherapy Induced Anemia 104

6.1.5 Research and Development Pipeline – Chemotherapy Induced Neutropenia 105

6.1.6 Research and Development Pipeline – Bone Metastases 106

6.2 Profiles of Promising Drugs in the Cancer Supportive Care Products Market 107

6.2.1 Xgeva/Prolia (denosumab) – Bone Metastases 107

6.2.2 Alpharadin – Bone Metastases 108

6.2.3 MAXY-G34 – Chemotherapy Induced Neutropenia 109

6.2.4 Lactermin – Oral Mucositis 109

6.2.5 Xen2174 – Cancer Pain 110

6.2.6 Tectin – Cancer Pain 111

6.2.7 NasalFent – Cancer Pain 112

7 Cancer Supportive Care Products Market: Competitive Landscape 113

7.1 Market Share Analysis 113

7.2 Competitive Profiling 114

7.2.1 Amgen 114

7.2.2 Johnson & Johnson 116

7.2.3 F. Hoffmann-La Roche 118

7.2.4 Novartis 120

7.2.5 Pfizer 122

8 Cancer Supportive Care Products Market: Deals Landscape 124

8.1 M&A and Licensing Agreements 124

8.1.1 Deals by Year 124

8.1.2 Deals by Deal Type 125

8.1.3 Deals by Indication 126

8.1.4 Deals by Value ($m) 127

8.1.5 Deals by Geography 128

8.1.6 Major Acquisitions in the Cancer Supportive Care Products Market 128

8.1.7 Major Licensing Agreements in the Cancer Supportive Care Products Market 129

9 Cancer Supportive Care Products Market: Appendix 131

9.1 Market Definitions 131

9.2 Abbreviations 131

9.3 Research Methodology 133

9.3.1 Coverage 133

9.3.2 Primary Research 134

9.3.3 Forecasts 134

9.3.4 Expert Panel Validation 136

9.4 Contact Us 137

9.5 Disclaimer 137

9.6 Sources 137

List of Tables

1.1 List of Tables

Table 1: Cancer Supportive Care Products Market, Global, Revenue ($m), 2001–2009 13

Table 2: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2009–2016 13

Table 3: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2001–2009 14

Table 4: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2009–2016 14

Table 5: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2001–2009 16

Table 6: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2009–2016 17

Table 7: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2009 20

Table 8: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2009-2016 20

Table 9: Oral Mucositis and Dry Mouth, Global, Revenue ($m), 2001–2009 29

Table 10: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 2009–2016 29

Table 11: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2001–2009 30

Table 12: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2009–2016 30

Table 13: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern ('000), 2001–2009 31

Table 14: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern ('000), 2009–2016 31

Table 15: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2001–2009 35

Table 16: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2009–2016 35

Table 17: Chemotherapy Induced Nausea and Vomiting, Emetic Risk Levels of Major Chemotherapeutic Agents 39

Table 18: Chemotherapy Induced Nausea and Vomiting, Global, Revenue ($m), 2001–2009 40

Table 19: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 2009–2016 40

Table 20: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2001–2009 41

Table 21: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2009–2016 41

Table 22: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern ('000), 2001–2009 42

Table 23: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern ('000), 2009–2016 42

Table 24: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2001–2009 46

Table 25: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2009–2016 46

Table 26: Cancer Pain, Global, Revenue ($m), 2001–2009 49

Table 27: Cancer Pain, Global, Revenue Forecast ($m), 2009–2016 50

Table 28: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2009 50

Table 29: Cancer Pain, Global, Annual Cost of Therapy ($), 2009-2016 50

Table 30: Cancer Pain, Global, Treatment Usage Patterns ('000), 2001-2009 51

Table 31: Cancer Pain, Global, Treatment Usage Patterns ('000), 2009-2016 52

Table 32: Cancer Pain, Geographical Segmentation, Revenue ($m), 2001–2009 57

Table 33: Cancer Pain, Geographical Segmentation, Revenue ($m), 2009–2016 57

Table 34: Chemotherapy Induced Anemia, Global, Revenue ($m), 2001–2009 61

Table 35: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 2009–2016 61

Table 36: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2001–2009 62

Table 37: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2009–2016 62

Table 38: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern ('000), 2001–2009 63

Table 39: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern ('000), 2009–2016 63

Table 40: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2001–2009 67

Table 41: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2009–2016 67

Table 42: Chemotherapy Induced Neutropenia, Global, Revenue ($m), 2001–2009 71

Table 43: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 2009–2016 71

Table 44: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2001–2009 72

Table 45: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2009–2016 72

Table 46: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern ('000), 2001–2009 73

Table 47: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern ('000), 2009–2016 73

Table 48: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2001–2009 77

Table 49: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2009–2016 77

Table 50: Bone Metastases, Global, Revenue ($m), 2001–2009 80

Table 51: Bone Metastases, Global, Revenue Forecast ($m), 2009–2016 80

Table 52: Bone Metastases, Global, Annual Cost of Therapy ($), 2001–2009 81

Table 53: Bone Metastases, Global, Annual Cost of Therapy ($), 2009–2016 81

Table 54: Bone Metastases, Global, Treatment Usage Pattern ('000), 2001–2009 82

Table 55: Bone Metastases, Global, Treatment Usage Pattern ('000), 2009–2016 82

Table 56: Bone Metastases, Geographical Segmentation, Revenue ($m), 2001–2009 86

Table 57: Bone Metastases, Geographical Segmentation, Revenue ($m), 2009–2016 86

Table 58: Cancer Supportive Care Products Market, the US, Revenue ($m), 2001–2009 89

Table 59: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 2009–2016 89

Table 60: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2001–2009 90

Table 61: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2009–2016 90

Table 62: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue ($m), 2001–2009 92

Table 63: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 2009–2016 92

Table 64: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2001–2009 93

Table 65: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2009–2016 94

Table 66: Cancer Supportive Care Products Market, Japan, Revenue ($m), 2001–2009 96

Table 67: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 2009–2016 96

Table 68: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2001–2009 97

Table 69: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2009–2016 97

Table 70: Cancer Supportive Care Products Market, Global, Pipeline Products – Amgen, 2011 115

Table 71: Cancer Supportive Care Products Market, Global, Pipeline Products – Johnson & Johnson, 2011 117

Table 72: Cancer Supportive Care Products Market, Global, Pipeline Products – F. Hoffmann-La Roche, 2011 119

Table 73: Cancer Supportive Care Products Market, Global, Pipeline Products – Novartis, 2011 121

Table 74: Cancer Supportive Care Products Market, Global, Pipeline Products – Pfizer, 2011 123

List of Figures

1.2 List of Figures

Figure 1: Cancer Supportive Care Products Market, Global, Revenue Forecast ($m), 2001–2016 13

Figure 2: Cancer Supportive Care Products Market, Global, Average Annual Cost of Therapy ($), 2001–2016 14

Figure 3: Cancer Supportive Care Products Market, Global, Market Share by Indication (%), 2009 and 2016 15

Figure 4: Cancer Supportive Care Products Market, Geographical Segmentation, Revenue ($m), 2001–2016 16

Figure 5: Cancer Supportive Care Products Market, Market Share by Geography (%), 2009 and 2016 18

Figure 6: Cancer Supportive Care Products Market, Market Share of the Top Five Countries of Europe (%), 2009 and 2016 19

Figure 7: Cancer Supportive Care Products Market, Sales of Generics Versus Branded Drugs ($m), 2001-2016 20

Figure 8: Oral Mucositis and Dry Mouth, World Health Organization Toxicity-based Classification for Oral Mucositis, 2011 28

Figure 9: Oral Mucositis and Dry Mouth, Global, Revenue Forecast ($m), 2001–2016 29

Figure 10: Oral Mucositis and Dry Mouth, Global, Annual Cost of Therapy ($), 2001–2016 30

Figure 11: Oral Mucositis and Dry Mouth, Global, Treatment Usage Pattern ('000), 2001–2016 31

Figure 12: Oral Mucositis and Dry Mouth, Global, Prevalence Population ('000), 2001–2016 32

Figure 13: Oral Mucositis and Dry Mouth, Global, Prescription Population ('000), 2001–2016 33

Figure 14: Oral Mucositis and Dry Mouth, Geographical Segmentation, Revenue ($m), 2001–2016 34

Figure 15: Oral Mucositis and Dry Mouth, Market Share by Geography (%), 2009 and 2016 36

Figure 16: Oral Mucositis and Dry Mouth, Market Share of Top Five Countries of Europe (%), 2009 and 2016 37

Figure 17: Chemotherapy Induced Nausea and Vomiting, Classification and Risk Factors, 2011 38

Figure 18: Chemotherapy Induced Nausea and Vomiting, Global, Revenue Forecast ($m), 2001–2016 40

Figure 19: Chemotherapy Induced Nausea and Vomiting, Global, Annual Cost of Therapy ($), 2001–2016 41

Figure 20: Chemotherapy Induced Nausea and Vomiting, Global, Treatment Usage Pattern ('000), 2001–2016 42

Figure 21: Chemotherapy Induced Nausea and Vomiting, Global, Prevalence Population ('000), 2001–2016 43

Figure 22: Chemotherapy Induced Nausea and Vomiting, Global, Prescription Population ('000), 2001–2016 44

Figure 23: Chemotherapy Induced Nausea and Vomiting, Geographical Segmentation, Revenue ($m), 2001–2016 46

Figure 24: Chemotherapy Induced Nausea and Vomiting, Market Share by Geography (%), 2009 and 2016 47

Figure 25: Chemotherapy Induced Nausea and Vomiting, Market Share of Top Five Countries of Europe (%), 2009 and 2016 48

Figure 26: Cancer Pain, Global, Revenue Forecast ($m), 2001–2016 49

Figure 27: Cancer Pain, Global, Annual Cost of Therapy ($), 2001-2016 50

Figure 28: Cancer Pain, Global, Treatment Usage Patterns ('000), 2001-2016 51

Figure 29: Cancer Pain, Global, Prevalence Population ('000), 2001-2016 52

Figure 30: Cancer Pain, Global, Treatment Seeking Population ('000), 2001-2016 53

Figure 31: Cancer Pain, Global, Diagnosed Population ('000), 2001-2016 54

Figure 32: Cancer Pain, Global, Prescription Population ('000), 2001-2016 55

Figure 33: Cancer Pain, Geographical Segmentation, Revenue ($m), 2001–2016 57

Figure 34: Cancer Pain, Market Share by Geography (%), 2009 and 2016 58

Figure 35: Cancer Pain, Market Share of Top Five Countries of Europe (%), 2009 and 2016 59

Figure 36: Chemotherapy Induced Anemia, Global, Revenue Forecast ($m), 2001–2016 60

Figure 37: Chemotherapy Induced Anemia, Global, Annual Cost of Therapy ($), 2001–2016 62

Figure 38: Chemotherapy Induced Anemia, Global, Treatment Usage Pattern ('000), 2001–2016 63

Figure 39: Chemotherapy Induced Anemia, Global, Prevalence Population ('000), 2001–2016 64

Figure 40: Chemotherapy Induced Anemia, Global, Prescription Population ('000), 2001–2016 65

Figure 41: Chemotherapy Induced Anemia, Geographical Segmentation, Revenue ($m), 2001–2016 67

Figure 42: Chemotherapy Induced Anemia, Market Share by Geography (%), 2009 and 2016 68

Figure 43: Chemotherapy Induced Anemia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 69

Figure 44: Chemotherapy Induced Neutropenia, National Cancer Institute's Common Toxicity Criteria for CINP, 2011 70

Figure 45: Chemotherapy Induced Neutropenia, Global, Revenue Forecast ($m), 2001–2016 71

Figure 46: Chemotherapy Induced Neutropenia, Global, Annual Cost of Therapy ($), 2001–2016 72

Figure 47: Chemotherapy Induced Neutropenia, Global, Treatment Usage Pattern ('000), 2001–2016 73

Figure 48: Chemotherapy Induced Neutropenia, Global, Prevalence Population ('000), 2001–2016 74

Figure 49: Chemotherapy Induced Neutropenia, Global, Prescription Population ('000), 2001–2016 75

Figure 50: Chemotherapy Induced Neutropenia, Geographical Segmentation, Revenue ($m), 2001–2016 77

Figure 51: Chemotherapy Induced Neutropenia, Market Share by Geography (%), 2009 and 2016 78

Figure 52: Chemotherapy Induced Neutropenia, Market Share of Top Five Countries of Europe (%), 2009 and 2016 79

Figure 53: Bone Metastases, Global, Revenue Forecast ($m), 2001–2016 80

Figure 54: Bone Metastases, Global, Annual Cost of Therapy ($), 2001–2016 81

Figure 55: Bone Metastases, Global, Treatment Usage Pattern ('000), 2001–2016 82

Figure 56: Bone Metastases, Global, Prevalence Population ('000), 2001–2016 83

Figure 57: Bone Metastases, Global, Prescription Population ('000), 2001–2016 84

Figure 58: Bone Metastases, Geographical Segmentation, Revenue ($m), 2001–2016 86

Figure 59: Bone Metastases, Market Share by Geography (%), 2009 and 2016 87

Figure 60: Bone Metastases, Market Share of Top Five Countries of Europe (%), 2009 and 2016 88

Figure 61: Cancer Supportive Care Products Market, the US, Revenue Forecast ($m), 2001–2016 89

Figure 62: Cancer Supportive Care Products Market, the US, Average Annual Cost of Therapy ($), 2001–2016 90

Figure 63: Cancer Supportive Care Products Market, the US, Market Share by Indication (%), 2009 and 2016 91

Figure 64: Cancer Supportive Care Products Market, Top Five Countries of Europe, Revenue Forecast ($m), 2001–2016 92

Figure 65: Cancer Supportive Care Products Market, Top Five Countries of Europe, Average Annual Cost of Therapy ($), 2001–2016 93

Figure 66: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Indication (%), 2009 and 2016 94

Figure 67: Cancer Supportive Care Products Market, Top Five Countries of Europe, Market Share by Country (%), 2009 and 2016 95

Figure 68: Cancer Supportive Care Products Market, Japan, Revenue Forecast ($m), 2001–2016 96

Figure 69: Cancer Supportive Care Products Market, Japan, Average Annual Cost of Therapy ($), 2001–2016 97

Figure 70: Cancer Supportive Care Products Market, Japan, Market Share by Indication (%), 2009 and 2016 98

Figure 71: Cancer Supportive Care Products, Global, Pipeline by Indication, 2010 99

Figure 72: Cancer Supportive Care Products, Global, Pipeline by Phase (%), 2010 100

Figure 73: Oral Mucositis and Dry Mouth, Global, Pipeline by Phase (%), 2010 101

Figure 74: Chemotherapy Induced Nausea and Vomiting, Global, Pipeline by Phase (%), 2010 102

Figure 75: Cancer Pain, Global, Pipeline by Phase (%), 2010 103

Figure 76: Chemotherapy Induced Anemia, Global, Pipeline by Phase (%), 2010 104

Figure 77: Chemotherapy Induced Neutropenia, Global, Pipeline by Phase (%), 2010 105

Figure 78: Bone Metastases, Global, Pipeline by Phase (%), 2010 106

Figure 79: Cancer Supportive Care Products Market, Global, Market Share by Companies (%), 2009 113

Figure 80: Cancer Supportive Care Products Market, Amgen SWOT Analysis, 2011 116

Figure 81: Cancer Supportive Care Products Market, Johnson & Johnson SWOT Analysis, 2011 118

Figure 82: Cancer Supportive Care Products Market, F. Hoffmann-La Roche SWOT Analysis, 2011 119

Figure 83: Cancer Supportive Care Products Market, Novartis SWOT Analysis, 2011 121

Figure 84: Cancer Supportive Care Products Market, Pfizer SWOT Analysis, 2011 123

Figure 85: Cancer Supportive Care Products Market, Global, M&A and Licensing Agreements by Year, 2008–2010 124

Figure 86: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Type, 2008–2010 125

Figure 87: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Indication, 2008–2010 126

Figure 88: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Deal Value, 2008–2010 127

Figure 89: Cancer Supportive Care Products Market, Global, M&As and Licensing Agreements by Geography, 2008–2010 128

Figure 90: GBI Research Market Forecasting Model 136

To order this report:

: Cancer Supportive Care Products Market to 2016 - Market is Expected to Decline after 2014 Due to Generic Erosion and Entry of Biosimilars

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:
Nicolas Bombourg
Reportlinker
Email: nbo@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com